Welcome to our dedicated page for Conmed news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on Conmed stock.
CONMED Corporation (NYSE: CNMD) is a medical equipment company in the surgical and medical instrument manufacturing industry. Its products are used in sports medicine procedures and general surgeries across specialties such as orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. The CONMED news feed on this page aggregates company-issued press releases and other coverage related to its operations, strategy and financial performance.
Recent news highlights include updates on portfolio optimization, such as CONMED’s announced intent to exit its gastroenterology product lines and to conclude a distribution agreement for a biliary stent product. The company has linked this decision to a focus on core markets in minimally invasive, robotic and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair. News items also cover quarterly and year-to-date financial results, where CONMED reports net sales by orthopedic and general surgery categories, and by single-use and capital products, along with domestic and international growth metrics.
Investors and observers can also follow governance and leadership developments through this news stream. CONMED has issued releases about changes to its Board of Directors, including the appointment of a new independent director and the resignation of another director to take a leadership role at another organization. The company has also announced a planned transition of its Chief Financial Officer, describing the timing and advisory period associated with that change.
Other news topics include capital allocation decisions, such as the declaration of a quarterly cash dividend and the subsequent authorization of a share repurchase program with suspension of the dividend, as well as participation in healthcare investment conferences where CONMED presents investor materials and financial guidance. Users interested in CNMD can use this page to review these types of announcements over time and to see how the company describes its strategy, operations and financial outlook.
CONMED (NYSE: CNMD) announced that Todd Garner will step down as Chief Financial Officer effective March 15, 2026 and will remain in an advisory role through November 2, 2026. The company has started a comprehensive search, supported by a leading executive search firm, to identify a new CFO. Management thanked Garner for eight years of service and said his departure is not related to any disagreement over financial statements or disclosures. CONMED also reaffirmed its full-year 2025 consolidated revenue and adjusted EPS guidance previously issued on November 5, 2025.
CONMED (NYSE: CNMD) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 3:00 p.m. PT / 6:00 p.m. ET in San Francisco.
Presenters will be Patrick J. Beyer, president and CEO, and Todd W. Garner, EVP and CFO. A live audio webcast will be available via the company’s Investors page at www.conmed.com, with a replay accessible after the event.
CONMED (NYSE: CNMD) will report fourth quarter 2025 financial results after market close on January 28, 2026. Management will host a conference call the same day at 4:30 p.m. ET to discuss results.
Investors can pre-register for telephone access to receive a dial-in number and passcode. The call will be webcast from the Investors section at www.conmed.com, and a webcast replay will be available about one hour after the call ends.
CONMED (NYSE: CNMD) announced it will exit its gastroenterology product lines and conclude its U.S. and Canadian distribution agreement for the Gore® VIABIL® biliary stent effective January 1, 2026. The company expects gastroenterology to generate $90–$95 million in 2025 with gross margins near 45%. CONMED forecasts EPS dilution of $0.45–$0.55 in 2026 from the exit and an improvement to consolidated gross margin of approximately +80 basis points after the exit completes. Proceeds from the Gore transaction are planned for general corporate purposes including strategic investments, debt paydown, and share repurchases. CONMED reaffirmed its 2025 revenue guidance of $1.365–$1.372 billion and adjusted EPS $4.48–$4.53, and will provide full 2026 guidance on its Q4 2025 earnings call.
CONMED (NYSE: CNMD) reported Q3 2025 sales of $337.9M, up 6.7% YoY (6.3% constant currency). GAAP diluted EPS was $0.09 vs. $1.57 a year ago; adjusted diluted EPS was $1.08 vs. $1.05 a year ago. Gross margin declined to 49.2% from 56.5% in Q3 2024. The Board authorized a $150.0M share repurchase program, suspended the quarterly cash dividend, and expects to repurchase at least $25.0M annually beginning in 2026.
Full-year 2025 revenue guidance is updated to $1.365B–$1.372B. Adjusted diluted EPS guidance is $4.48–$4.53 (FX headwind ~$0.10); recent tariffs are estimated to reduce Q4 EPS by ~$0.07. Management held a conference call on Nov 5, 2025.
CONMED (NYSE: CNMD) will report Q3 2025 financial results after market close on Wednesday, November 5, 2025. Management will host a conference call at 4:30 p.m. ET the same day to discuss results. Participants can pre-register by phone to obtain dial-in number and passcode. The call will be webcast from the Investors section at www.conmed.com. A webcast replay will be available on the same site approximately one hour after the end of the call.
CONMED Corporation (NYSE: CNMD) has appointed Kim Kelderman to its Board of Directors, effective September 8, 2025. Kelderman currently serves as President, CEO, and Board member of Bio-Techne (NASDAQ: TECH) since February 2024.
Kelderman brings extensive experience in life sciences, having previously held leadership positions at Thermo Fisher Scientific, where he led multiple businesses and managed the Platforms and Content of the Genetic Sciences Division. Prior to that, he served as Senior Segment Leader at Becton Dickinson, overseeing the global Blood Tubes "Vacutainer" business.
CONMED Corporation (NYSE: CNMD) has announced a quarterly cash dividend of $0.20 per share. The dividend was declared by the Board of Directors on August 7, 2025. Shareholders of record as of September 15, 2025 will receive the dividend payment on October 3, 2025.
CONMED Corporation (NYSE: CNMD) reported Q2 2025 financial results with sales of $342.3 million, representing a 3.1% year-over-year increase. The company's domestic revenue grew 2.8%, while international revenue rose 3.4%. GAAP diluted EPS decreased to $0.69 from $0.96 in Q2 2024, while adjusted diluted EPS improved to $1.15 from $0.98.
The company updated its 2025 guidance, now expecting full-year revenue between $1.356-1.378 billion and adjusted diluted EPS of $4.40-$4.55. This guidance includes an estimated $0.09 EPS negative impact from recent tariff announcements in H2 2025.
Single-use products showed strong performance with 6.6% growth, while capital products declined 15.5%. The company's focus remains on strengthening supply chain operations and executing on four key growth drivers.
CONMED Corporation (NYSE: CNMD) announced that Martha Aronson will step down from its Board of Directors, effective July 7, 2025, to become President and CEO of Merit Medical. Aronson, who joined CONMED's Board in February 2016 and served as Board Chair, has been recognized for her strategic insights and contributions to the company's growth and governance.
The announcement includes statements from Pat Beyer, CONMED's President and CEO, and LaVerne Council, current Chair of the Board, both acknowledging Aronson's valuable service and leadership during her tenure since 2016.
FAQ
What is the current stock price of Conmed (CNMD)?
What is the market cap of Conmed (CNMD)?
